ExpreS2ion Biotech Holding
1,42 SEK +1,57 %HC Andersen Capital saa maksun yhtiöltä ExpreS2ion Biotech Holding DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Lue lisääAnalyst
Viimeisimmät videot
Pörssikalenteri
Suurimmat omistajatLähde: Millistream Market Data AB
| Omistaja | Osuus | Ääniä |
|---|---|---|
| Saxo Bank A/S Client Assets | 7,8 % | 7,8 % |
| Sydbank A/S | 5,5 % | 5,5 % |
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.
